Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485781 | 1.00 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15301051 | 0.84 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25181459 | 0.82 | TSHR (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2299466 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2296542 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL21779357 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25181383 | 0.82 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18742045 | 0.82 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2292617 | 0.80 | PRKAB2 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25185209 | 0.80 | SLC6A3 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265402-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-07-24 | — | — | US | claimed |
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | claimed |
| EP-0924204-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-06-23 | — | — | EP | claimed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2024222860-A1 | SALT OF MORPHOLINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-118852146-A | Crystal form of morpholine heterocyclic compound, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4444316-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4428128-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| EP-0924204-A4 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-6265402-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6265402-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6265402-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0924204-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924204-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008828-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | NIKKEN CHEMICALS CO., LTD. (JP) | 1998-03-05 | — | — | WO | disclosed |
| EP-0111809-A1 | Pyrazolo(4.3-b)(1.4)oxazines, processes for their preparation and their use as medicaments | Troponwerke GmbH & Co. KG (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | PRKAB2 895/4885PRKAG1 339/4885PRKAA2 1264/4885 |
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TAAR1, TAAR5, AVPR2 | PRKAB2 4152/4885PRKAG1 4427/4885PRKAA2 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.